Overview

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Status:
Unknown status

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes. However, how DPP-4 inhibitors or SGLT2 inhibitors exert protective actions for diabetic complications in addition to their glucose-lowering effects remains unknown.

Phase:

Phase 4

Details

Lead Sponsor:

Kurume University

Treatments:

Glimepiride
Sodium-Glucose Transporter 2 Inhibitors